{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:30:45Z","timestamp":1766467845526},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10072-012-0952-x","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T06:39:24Z","timestamp":1327991964000},"page":"93-98","source":"Crossref","is-referenced-by-count":16,"title":["Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington\u2019s disease patients"],"prefix":"10.1007","volume":"34","author":[{"given":"Miroslav","family":"Cuturic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth K.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine M.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea A.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"key":"952_CR1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/exnr.1999.7135","volume":"159","author":"Q Chen","year":"1999","unstructured":"Chen Q, Surmeier DJ, Reiner A (1999) NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization. Exp Neurol 159:283\u2013296","journal-title":"Exp Neurol"},{"key":"952_CR2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1074\/mcp.M500090-MCP200","volume":"4","author":"M Perluigi","year":"2005","unstructured":"Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, Cini C, De Marco C, Butterfield DA (2005) Proteomic analysis of protein expression and oxidative modification in r6\/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 4:1849\u20131861","journal-title":"Mol Cell Proteomics"},{"key":"952_CR3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","volume":"254","author":"N Klepac","year":"2007","unstructured":"Klepac N, Relja M, Klepac R, He\u0107imovi\u0107 S, Babi\u0107 T, Trkulja V (2007) Oxidative stress parameters in plasma of Huntington\u2019s disease patients, asymptomatic Huntington\u2019s disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 254:1676\u20131683","journal-title":"J Neurol"},{"issue":"Pt 6","key":"952_CR4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","volume":"119","author":"A Antonini","year":"1996","unstructured":"Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Y\u00e9benez JG, Boesiger P, Weindl A, Maguire RP (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain 119(Pt 6):2085\u20132095","journal-title":"Brain"},{"key":"952_CR5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0896-6273(92)90165-A","volume":"9","author":"LJ Martin","year":"1992","unstructured":"Martin LJ, Blackstone CD, Huganir RL, Price DL (1992) Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9:259\u2013270","journal-title":"Neuron"},{"key":"952_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","volume":"315","author":"G Schilling","year":"2001","unstructured":"Schilling G, Coonfield ML, Ross CA, Borchelt DR (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington\u2019s disease transgenic mouse model. Neurosci Lett 315:149\u2013153","journal-title":"Neurosci Lett"},{"key":"952_CR7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1196\/annals.1320.003","volume":"1033","author":"CJ Rebouche","year":"2004","unstructured":"Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann N Y Acad Sci 1033:30\u201341","journal-title":"Ann N Y Acad Sci"},{"key":"952_CR8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200342110-00002","volume":"42","author":"AM Evans","year":"2003","unstructured":"Evans AM, Fornasini G (2003) Pharmacokinetics of l-carnitine. Clin Pharmacokinet 42:941\u2013967","journal-title":"Clin Pharmacokinet"},{"key":"952_CR9","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.metabol.2009.05.014","volume":"58","author":"M Malaguarnera","year":"2009","unstructured":"Malaguarnera M, Vacante M, Motta M, Malaguarnera M, Volti GL, Galvano F (2009) Effect of l-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism 58:1618\u20131623","journal-title":"Metabolism"},{"key":"952_CR10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3945\/ajcn.2008.26251","volume":"89","author":"M Malaguarnera","year":"2009","unstructured":"Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M (2009) l-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 89:71\u201376","journal-title":"Am J Clin Nutr"},{"key":"952_CR11","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1517\/14656560903081745","volume":"10","author":"F Galvano","year":"2006","unstructured":"Galvano F, Volti GL, Malaguarnera M, Avitabile T, Antic T, Vacante M, Malaguarnera M (2006) Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother 10:1875\u20131882","journal-title":"Expert Opin Pharmacother"},{"key":"952_CR12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0531-5565(01)00116-4","volume":"6","author":"PJA Rani","year":"2001","unstructured":"Rani PJA, Panneerselvam C (2001) Carnitine as a free radical scavenger in aging. Exp Gerontol 6:1713\u20131726","journal-title":"Exp Gerontol"},{"key":"952_CR13","first-page":"387","volume":"43","author":"J Koudelov\u00e1","year":"1994","unstructured":"Koudelov\u00e1 J, Mourek J, Drahota Z, Rauchov\u00e1 H (1994) Protective effect of carnitine on lipoperoxide formation in rat brain. Physiol Res 43:387\u2013389","journal-title":"Physiol Res"},{"key":"952_CR14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ajcn\/86.6.1738","volume":"86","author":"M Malaguarnera","year":"2007","unstructured":"Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M (2007) l-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. Am J Clin Nutr 86:1738\u20131744","journal-title":"Am J Clin Nutr"},{"key":"952_CR15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11011-011-9260-z","volume":"26","author":"M Malaguarnera","year":"2011","unstructured":"Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, Rampello L, Pennisi G (2011) Acetyl-l-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 26:281\u2013289","journal-title":"Metab Brain Dis"},{"key":"952_CR16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3109\/00365521.2011.565067","volume":"46","author":"M Malaguarnera","year":"2011","unstructured":"Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G (2011) Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 46:750\u2013759","journal-title":"Scand J Gastroenterol"},{"key":"952_CR17","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1007\/s10620-006-9187-0","volume":"51","author":"M Malaguarnera","year":"2006","unstructured":"Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L (2006) Effects of l-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 51:2242\u20132247","journal-title":"Dig Dis Sci"},{"key":"952_CR18","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.3748\/wjg.v11.i45.7197","volume":"11","author":"M Malaguarnera","year":"2005","unstructured":"Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R (2005) Effects of l-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 11:7197\u20137202","journal-title":"World J Gastroenterol"},{"key":"952_CR19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2146\/ajhp110049","volume":"69","author":"CM Mock","year":"2012","unstructured":"Mock CM, Schwetschenau KH (2012) Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. Am J Health Syst Pharm 69:35\u201339","journal-title":"Am J Health Syst Pharm"},{"key":"952_CR20","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.biopha.2009.06.020","volume":"64","author":"E Vamos","year":"2010","unstructured":"Vamos E, Voros K, Vecsei L, Klivenyi P (2010) Neuroprotective effects of l-carnitine in a transgenic animal model of Huntington\u2019s disease. Biomed Pharmacother 64:282\u2013286","journal-title":"Biomed Pharmacother"},{"key":"952_CR21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"M Folstein","year":"1975","unstructured":"Folstein M, Folstein SE, McHugh PR (1975) \u201cMini-Mental State\u201d a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"952_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s Disease Rating Scale: reliability and consistency. Mov Disord 11:136\u2013142","journal-title":"Mov Disord"},{"key":"952_CR23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0002-8223(96)00257-X","volume":"96","author":"National Academy of Sciences","year":"1996","unstructured":"National Academy of Sciences (1996) Summary of WIC nutrition risk criteria: a scientific assessment. Committee on Scientific Evaluation of WIC Nutrition Risk Criteria Food and Nutrition Board, Institute of Medicine. J Am Diet Assoc 96:925\u2013930","journal-title":"J Am Diet Assoc"},{"issue":"1","key":"952_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/15622975.2010.489619","volume":"12","author":"M Cuturic","year":"2011","unstructured":"Cuturic M, Abramson RK, Moran RR, Hardin JW, Hall AV (2011) Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients. World J Biol Psychiatry 12(1):73\u201379","journal-title":"World J Biol Psychiatry"},{"key":"952_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.pra.0000367773.03636.d1","volume":"16","author":"M Cuturic","year":"2010","unstructured":"Cuturic M, Abramson RK, Moran RR, Hardin JW (2010) Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. J Psychiatr Pract 16:5\u201314","journal-title":"J Psychiatr Pract"},{"key":"952_CR26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.c.30087","volume":"142C","author":"N Longo","year":"2006","unstructured":"Longo N, di San Amat, Filippo C, Pasquali M (2006) Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 142C:77\u201385","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"952_CR27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s004310050732","volume":"156","author":"F Proulx","year":"1997","unstructured":"Proulx F, Lacroix J, Qureshi IA, Nadeau D, Gauthier M, Lambert M (1997) Acquired carnitine abnormalities in critically ill children. Eur J Pediatr 156:864\u2013869","journal-title":"Eur J Pediatr"},{"key":"952_CR28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0026-0495(92)90146-2","volume":"41","author":"A Wennberg","year":"1992","unstructured":"Wennberg A, Hyltander A, Sj\u00f6berg A, Arfvidsson B, Sandstr\u00f6m R, Wickstr\u00f6m I, Lundholm K (1992) Prevalence of carnitine depletion in critically ill patients with undernutrition. Metabolism 41:165\u2013171","journal-title":"Metabolism"},{"key":"952_CR29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.braindev.2005.11.005","volume":"28","author":"G Coppola","year":"2006","unstructured":"Coppola G, Epifanio G, Auricchio G, Federico RR, Resicato G, Pascotto A (2006) Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev 28:358\u2013365","journal-title":"Brain Dev"},{"key":"952_CR30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/1531-8249(200001)47:1<64::AID-ANA11>3.0.CO;2-S","volume":"47","author":"RE Pratley","year":"2000","unstructured":"Pratley RE, Salbe AD, Ravussin E, Caviness JN (2000) Higher sedentary energy expenditure in patients with Huntington\u2019s disease. Ann Neurol 47:64\u201370","journal-title":"Ann Neurol"},{"key":"952_CR31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0887-8994(90)90037-2","volume":"6","author":"GN Breningstall","year":"1990","unstructured":"Breningstall GN (1990) Carnitine deficiency syndromes. Pediatr Neurol 6:75\u201381","journal-title":"Pediatr Neurol"},{"key":"952_CR32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/cc3742","volume":"9","author":"PE Lheureux","year":"2005","unstructured":"Lheureux PE, Penaloza A, Zahir S et al (2005) Science review: carnitine in the treatment of valproic acid-induced toxicity\u2014what is the evidence? Crit Care 9:431\u2013440","journal-title":"Crit Care"},{"issue":"suppl. 2","key":"952_CR33","first-page":"8","volume":"10","author":"R Pons","year":"1995","unstructured":"Pons R, De Vivo DC (1995) Primary and secondary carnitine deficiency syndromes. J Child Neurol 10(suppl. 2):8\u201324","journal-title":"J Child Neurol"},{"key":"952_CR34","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1007\/s10620-008-0238-6","volume":"53","author":"M Malaguarnera","year":"2008","unstructured":"Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, Rampello L (2008) Acetyl-l-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 53:3018\u20133025","journal-title":"Dig Dis Sci"},{"key":"952_CR35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/mds.870050317","volume":"5","author":"CG Goety","year":"1990","unstructured":"Goety CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, Fariello RG (1990) l-Acetyl-carnitine in Huntington\u2019s disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 5:263\u2013265","journal-title":"Mov Disord"},{"key":"952_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1024\/0300-9831.75.1.3","volume":"75","author":"K Eder","year":"2005","unstructured":"Eder K, Felgner J, Becker K et al (2005) Free and total carnitine concentrations in pig plasma after oral ingestion of various l-carnitine compounds. Int J Vitam Nutr Res 75:3\u20139","journal-title":"Int J Vitam Nutr Res"},{"key":"952_CR37","unstructured":"(2007) Carnitor (levocarnitine) prescribing information. Sigma-Tau Pharmaceuticals Inc, Gaithersburg"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-012-0952-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-012-0952-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-012-0952-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T02:17:02Z","timestamp":1561256222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-012-0952-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1007\/s10072-012-0952-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}